Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Cyclerion Therapeutics Inc.

NAS: CYCN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cyclerion Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 18, 2022, 5:22 p.m.

CYCN
/zigman2/quotes/207301221/composite

$

1.32

Change

+0.02 +1.54%

Volume

Volume 1

Quotes are delayed by 20 min

/zigman2/quotes/207301221/composite

Previous close

$ 1.39

$ 1.30

Change

-0.09 -6.47%

Day low

Day high

$1.27

$1.43

Open

52 week low

52 week high

$1.27

$6.90

Open

Company Description

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC sti...

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

40.52

Price to Book Ratio

1.75

Enterprise Value to EBITDA

-0.91

Enterprise Value to Sales

19.20

Total Debt to Enterprise Value

0.54

Efficiency

Revenue/Employee

67,529.00

Income Per Employee

-2,288,294.00

Receivables Turnover

2.87

Total Asset Turnover

0.02

Liquidity

Current Ratio

3.45

Quick Ratio

3.45

Cash Ratio

3.21

Profitability

Operating Margin

-3,355.18

Pretax Margin

-3,388.59

Net Margin

-3,388.59

Return on Assets

-51.55

Return on Equity

-98.97

Return on Total Capital

-55.65

Return on Invested Capital

-58.35

Capital Structure

Total Debt to Total Equity

76.87

Total Debt to Total Capital

43.46

Total Debt to Total Assets

39.64

Long-Term Debt to Equity

65.44

Long-Term Debt to Total Capital

37.00

Officers and Executives

Name Age Officer Since Title
Dr. Peter M. Hecht 55 2019 Chief Executive Officer & Director
Ms. Cheryl Gault - - Head-Strategy
Mr. Kevin Durfee - - Vice President-Information Technology & Facilities
Dr. Andreas Eugen Busch 55 2019 Chief Innovation Officer
Dr. G. Todd Milne - - Vice President-Corporate Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/03/2021 Peter M. Hecht
Chief Executive Officer; Director 		823,170   Acquisition at $3.28 per share. 2,699,997
06/03/2021 Polaris Growth Management LLC
Director 		3,322   Acquisition at $3.12 per share. 10,364
06/03/2021 Polaris Growth Management LLC
Director 		92,831   Acquisition at $3.12 per share. 289,632
06/03/2021 Slate Path Capital LP
961,538   Acquisition at $3.12 per share. 2,999,998
05/06/2021 Peter M. Hecht
Chief Executive Officer; Director 		302,000   Acquisition at $2.43 per share. 733,860
05/05/2021 Peter M. Hecht
Chief Executive Officer; Director 		398,001   Acquisition at $2.53 per share. 1,006,942
05/04/2021 Peter M. Hecht
Chief Executive Officer; Director 		300,000   Acquisition at $2.29 per share. 687,000
02/25/2021 Anjeza Gjino
Chief Financial Officer 		1,824   Disposition at $4 per share. 7,296
02/25/2021 Christopher I. Wright
Chief Medical Officer 		2,637   Disposition at $3.99 per share. 10,521
12/28/2020 Mark G. Currie
President and CSO 		20,107   Disposition at $3.01 per share. 60,522
11/09/2020 Andreas Eugen Busch
Chief Innovation Officer 		125,000   Acquisition at $2.53 per share. 316,250
11/06/2020 William I. Huyett
Chief Financial Officer 		3,827   Disposition at $2.52 per share. 9,644
02/21/2020 William I. Huyett
Chief Financial Officer 		3,559   Disposition at $5.12 per share. 18,222
12/30/2019 Mark G. Currie
President and CSO 		25,000   Disposition at $2.48 per share. 62,000
/news/latest/company/us/cycn

MarketWatch News on CYCN

  1. Cyclerion Therapeutics started at buy with $14 stock price target at Truist

    6:45 a.m. Oct. 20, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cycn

Other News on CYCN

  2. Warning: CYCN is at high risk of performing badly

    4:47 a.m. Nov. 12, 2021

    - Seeking Alpha

  4. Warning: CYCN is at high risk of performing badly

    3:38 a.m. Oct. 22, 2021

    - Seeking Alpha

  5. ME, CYCN and FWBI among pre market gainers

    7:28 a.m. Oct. 20, 2021

    - Seeking Alpha

  7. 10-Q: CYCLERION THERAPEUTICS, INC.

    4:01 p.m. July 29, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  8. DPW, ANVS and CFMS among pre market gainers

    7:30 a.m. July 23, 2021

    - Seeking Alpha

  14. Cyclerion climbs on a series of insider purchases

    8:29 a.m. June 8, 2021

    - Seeking Alpha

  15. WKHS, BNGO, CLOV and SFIX among notable premarket gainers

    7:26 a.m. June 8, 2021

    - Seeking Alpha

  17. SPCE, GTX, STEM and FTCI among premarket gainers

    7:18 a.m. May 24, 2021

    - Seeking Alpha

  19. TLRY, ET, ROKU and NET among premarket gainers

    7:25 a.m. May 7, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Cyclerion Therapeutics, Inc.

Riverview II

245 First Street

18th floor

Cambridge, Massachusetts 02142

Phone

1 8573278778

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$2.30M

Net Income

$-77.80M

Employees

34.00

Annual Report for CYCN

/news/pressrelease/company/us/cycn

Press Releases on CYCN

  11. Best Penny Stocks on Reddit to Buy? Check These 4 Out in June

    8:06 a.m. June 15, 2021

    - Penny Stocks

  13. Tuesday 6/8 Insider Buying Report: WSC, CYCN

    10:26 a.m. June 8, 2021

    - MarketNewsVideo.com

  19. Friday 5/7 Insider Buying Report: CYCN, WY

    9:32 a.m. May 7, 2021

    - MarketNewsVideo.com

  21. Loading more headlines...
Link to MarketWatch's Slice.